| Revenue growth | Q2 +16% YoY; H1 +10% YoY |
|---|---|
| Margins | Q2 EBITDA 34%, PAT 24%; H1 EBITDA 31%, PAT 22% |
| Demand visibility | Q2 YoY: Animal +37%, Industrial Bio +43%, Spec Mfg +25%, Human +6% |
Growth
Q2 revenue +16% YoY, +12% QoQ. EBITDA +20% YoY. PAT +14% YoY, +33% QoQ. H1 revenue +10%, PAT +5%.
Outlook
No explicit guidance. Emphasis on R&D, deeper geographic presence and inorganic expansion. No capex figures disclosed.
Risks
Non-food bio-processing down 7% YTD. Europe Q2 revenue down 10%. H1 PAT growth lags revenue. Human Nutrition flat in H1.
Last quarter's promises, checked
Delivered
- EBITDA margin 30-32% → Q2 34% (= BEAT)
- Double-digit growth rest of FY27 → Q2 revenue +16% YoY (= BEAT)
Partly delivered
- Q1 ₹10cr sales reversal to recover in Q2 → Q2 revenue +12% QoQ, recovery unconfirmed (= PARTIAL)
- Strong 2H biocatalysis growth → Industrial Bio +43% Q2 YoY, biocatalysis not split out (= PARTIAL)
- Human Nutrition 'strong momentum' → Human +6% Q2, H1 flat (= PARTIAL)
Missed
- FY27 capex ₹123cr (₹50cr R&D due next qtr) → capex not disclosed (= MISS)
- US growth 8-10% → no US figure; Human Nutrition H1 +0.4% (= MISS)
Investor Presentation filed with NSE, NSE: ADVENZYMES. Summary written with AI assistance from the document.
Advanced Enzyme Technologies Ltd: key numbers
- Share price
- ₹263.55
- Market cap
- ₹2,951 Cr
- Revenue (annual)
- ₹745.8 Cr
- Net profit (annual)
- ₹168.7 Cr
- P/E (TTM)
- 17.8×Sector 45.9×
- Promoter holding
- 43.56%+0.32% QoQ
- FII holding
- 26.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Advanced Enzyme Technologies Ltd
All →Advanced Enzyme Technologies Results Update
Advanced Enzyme Technologies issued a press release highlighting unaudited Q2 and half-year FY27 results. Revenue and profit grew year-on-year, with EBITDA and PAT margins reported.
Advanced Enzyme Technologies Q2 FY27 Results: Net Profit ₹51.2 Cr, Up 14.5% YoY
Advanced Enzyme Technologies Ltd reported revenue from operations of ₹214.5 Cr (+16.3% YoY) and net profit of ₹51.2 Cr (+14.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.2 Cr · +14.5% YoY
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme closed its buyback after purchasing 2,410,906 shares for ₹69.70 Crore. Closure took effect October 30, 2026, ahead of the scheduled period.
- Value
- ₹69.70 Cr
- Execution
- August 14, 2026 to October 30, 2026
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme Technologies bought back 54,455 equity shares via Emkay Global on October 29, 2026 at an average of ₹263.76. Cumulative buyback stands at 24,10,906 shares under the ongoing open-market programme.
- Value
- ₹1.44 Cr
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme bought back 64,583 shares on 28-10-2026 at an average ₹262.49, totalling 23,56,451 shares to date. Purchases were made via Emkay Global on the open market.
- Value
- ₹1.70 Cr
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme bought back 29,115 shares on October 27, 2026, worth about ₹0.75 Crore. Cumulative buyback stands at 22,91,868 shares under its open-market programme.
- Value
- ₹0.75 Cr